UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing a more effective and safe vaccine against a bacterium that annually kills…
FOMAT Medical Research testing promising antibody cocktail ‘REGN-COV2’ to treat, prevent COVID-19
An antibody cocktail called REGN-COV2 designed to treat and prevent coronavirus infection is being tested at FOMAT Medical Research in Oxnard. FOMAT is launching two clinical trials for COVID-19 treatment, the disease caused by the SARS-COV-2, on Thursday, reported CBS Los…
Novavax Secures $1.6 Billion from U.S. Government for COVID-19 Vaccine Program
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate, NVX‑CoV2373. Gaithersburg, Md.-based Novavax said the funding will allow…
Milken Institute Teams with First Person to Explain the Race to a COVID-19 Vaccine
WASHINGTON–(BUSINESS WIRE)– The Milken Institute, the nonprofit, nonpartisan think tank, and First Person, a San Francisco design and storytelling company, together tell the urgent story of the global race for a COVID-19 vaccine in a newly released interactive experience at: https://www.covid-19vaccinetracker.org/. Developed…
Johnson & Johnson: Clinical study of potential coronavirus vaccine could start by end of year
Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical Cos. has forged a partnership with the Beth Israel Deaconess Medical Center (BIDMC) to support coronavirus vaccine development. Janssen and the virology lab led by Dr. Dan Barouch at BIDMC have…
How is coronavirus vaccine development going in the U.S.?
Researchers in Pittsburgh and Boston are moving forward with research into two separate coronavirus vaccine programs against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. The work of the University of Pittsburgh School of Medicine researchers is detailed in a paper published recently…
A phase 3 study for chikungunya vaccine after passing midstage test
The chikungunya vaccine, known as MV-CHIK, hit its primary goal in the phase 2 trial, and Themis is now eyeing a move into phase 3. The company based its chikungunya shot on its measles vector platform, licensed from Institut Pasteur. In the…
Breakthrough in Designing a Better Salmonella Vaccine
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing a more effective and safe vaccine against a bacterium that annually kills…
The top 5 vaccine companies by 2017 revenue
Even in an industry dominated by a few huge companies, disruption happens sometimes—and 2017 was one of those times. GlaxoSmithKline surpassed Merck to top the vaccine industry by sales, generating $7 billion compared to Merck’s $6.5 billion. It stands to be…
Research Suggests New Vaccine Candidates for Malaria
Researchers have shown that higher levels of Plasmodium antibodies are protective against severe malaria in children living in Papua New Guinea. Children who have higher levels of antibodies to a specific short amino acid sequence in the malaria parasite, P. falciparum,…